CD274 and neoplasm: Blockading the PD-L1/PD-1 signaling pathway has been demonstrated as an important means to break tumor immune escape in a large number of clinical drugs [21,22,23], but sufficient immune cells are also a prerequisite for the sustained action of PD-1 blockers [24,25,26].